Insight

Karl Semaan: First-line systemic therapy following adjuvant immunotherapy in renal cell carcinoma

Karl Semaan/X

Aug 16, 2024, 14:16

Karl Semaan: First-line systemic therapy following adjuvant immunotherapy in renal cell carcinoma

Karl Semaan, Postdoctoral Research Fellow at Dana-Farber Cancer Institute, shared a post on X:

“Just in European Urology, our study on first-line systemic therapy following adjuvant immunotherapy in renal cell carcinoma.

Effort co-led with Talal El Zarif with amazing mentorship from Daniel Heng and Toni Choueiri.”

Source: Karl Semaan/X

Authors: Talal El Zarif, Karl Semaan, Wanling Xie, Marc Eid, Martin Zarba, Wadih Issa, Tian Zhang, Charles B. Nguyen, Ajjai Alva, Catherine C. Fahey, Kathryn E. Beckermann, Jose A. Karam, Matthew T. Campbell, Giuseppe Procopio, Marco Stellato, Sebastiano Buti, Anezka Zemankova, Bohuslav Melichar, Francesco Massari, Veronica Mollica, and Toni K. Choueiri.

adjuvant immunotherapy

adjuvant immunotherapy Ajjai Alva Anezka Zemankova Bohuslav Melichar cancer Catherine C. Fahey Charles B. Nguyen Daniel Heng european urology Francesco Massari Giuseppe Procopio Jose A. Karam Karl Semaan Kathryn E. Beckermann Marc Eid Marco Stellato Martin Zarba Matthew T Campbell OncoDaily Oncology renal cell carcinoma Sebastiano Buti Talal El Zarif Tian Zhang Toni Choueiri Toni K. Choueiri Veronica Mollica Wadih Issa Wanling Xie

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer